Biotronik said yesterday that its Orsiro stent tops the Xience stents made by Abbott (NYSE:ABT) when it comes to target lesion failure, according to data from a clinical trial. The randomized, controlled BioSTEMI trial was the first direct comparison between the two drug-eluting stents in patients with acute ST-segment elevation myocardial infarction (STEMI). Biotronik announced […]
CellAegis Devices
RIC device dev CellAegis raises $3.1m
Remote ischemic conditioning device developer CellAegis Devices has raised $3.1 million in a new round of equity financing, according to an SEC filing posted this week. The Toronto-based company developed and proceeds the AutoRIC device, a portable automated device that provides ‘point of care’ delivery of remote ischemic conditioning, according to the company’s website. The […]